Moody's affirms Alkermes' Ba3 CFR, outlook stable
Moody's Investors Service ("Moody's") affirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). The affirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating. There is no chang...Alkermes is a biopharmaceutical company. Co.'s products include: ARISTADA, which is an extended-release injectable suspension for the treatment of schizophrenia; VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence; INVEGA SUSTENNA/XEPLION, and RISPERDAL CONSTA, which is for the treatment of schizophrenia and for the treatment of schizoaffective disorder; AMPYRA/FAMPYRA, which is a treatment to improve walking in adults with multiple sclerosis; and BYDUREON is for the treatment of type 2 diabetes. Co.'s product candidate include Aripiprazole Lauroxil Two-Month Dose for the treatment of schizophrenia, among others.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.